Biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw: a systematic review

• Alejandro I. Lorenzo-Pouso ^[1] ; Mario Pérez-Sayáns ^[1] ; Sergio González-Palanca ^[3] ; Cintia Chamorro-Petronacci ^[1] ; José Bagán ^[2] ; Abel García-García ^[1]
  1. [1] Universidade de Santiago de Compostela

     Universidade de Santiago de Compostela

     Santiago de Compostela, España

     
  2. [2] Universitat de València

     Universitat de València

     Valencia, España

     
  3. [3] MD, PhD. Department of Gynecology & Obstetrics, Valdeorras Hospital, El Barco de Valdeorras, Spain

  Mostrar afiliaciones +
• Localización: Medicina oral, patología oral y cirugía bucal. Ed. inglesa, ISSN-e 1698-6946, Vol. 24, Nº. 1 (January ), 2019
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • The goal of this paper was to identify available biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw (BRONJ).

    Case-control studies comparing the different concentrations of a series of molecules detected in serum and urine as matrices of BRONJ affected patients vs. non-affected were included. PRISMA guidelines for systematic reviews were used for the present paper. Two reviewers independently screened electronic databases (Medline, Web of science, and The Cochrane Library) and performed hand searches. Risk of bias assessment of selected studies was performed by the Newcastle-Ottawa Scale. This study is registered as PROSPERO CRD42017078149.

    From a total of 601 identified studies, 7 (4 articles with high methodological quality and 3 with medium) articles were included. They investigate 2623 patients, of whom 91 (3.47%) developed BRONJ. A total of 7 biomarkers were identified and classified into 3 groups: bone turnover, angiogenesis and endocrine markers. Conflicting results were found in relation to most biomarkers.

    The present review suggests that no useful markers are currently available to evaluate BRONJ risk. Nevertheless, the present paper indicates that a paradigm shift from bone turnover biomarkers to angiogenesis and endocrine markers could shed light on this search.